skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Table of Contents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Appendix B: Drug Characteristics Tables

Characteristics of Fusion Inhibitor

(Last updated:January 29, 2008; last reviewed:May 01, 2014)

Click here to view this table as an image

Appendix B, Table 5. Characteristics of Fusion Inhibitor
Generic Name (Abbreviation)/ Trade Name Formulation Dosing Recommendation Serum Half-Life Elimination Storage Adverse Eventsa
Enfuvirtide
(T20)
Fuzeon
  • Injectable; supplied as lyophilized powder
  • Each vial contains 108 mg of T20; reconstitute with 1.1mL of sterile water for injection for delivery of approximately 90 mg/1 mL.
90 mg (1mL) subcutaneously BID 3.8 hours Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool Store at room temperature (up to 25º C or 77º F). Re-constituted solution should be refrigerated at 2º to 8ºC (36º to 46º F) and used within 24 hours.
  • Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in almost 100% of patients
  • Increased incidence of bacterial pneumonia
  • HSR (<1% of patients): Symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Re-challenge is not recommended.
a Also see Table 14.

Key to Abbreviations: BID = twice daily, HSR = hypersensitivity reaction, T20 = enfuvirtide

Back to Top